2014 中国肺癌高峰论坛访谈录

为了进一步推动中国肺癌研究的发展．中国抗癌协会临床肿瘤学协作专业委员会和中国抗癌协会肺癌专业委员会于2014年3月6—7日在广州举行了第十一届中国肺癌高峰论坛。此次会议的主题是“明智选择：常见的肺癌治疗决策”,来自全国各地从事肺癌和相关学科研究的500多位专家和学术带头人参加了此次会议。     

2013中国肺癌高峰论坛访谈录

为了进一步推动中国肺癌研究的发展,中国抗癌协会肺癌专业委员会和中国抗癌协会临床肿瘤学协作专业委员会于2013年3月8-9日在广州举行了第十届中国肺癌高峰论坛.此次会议的主题是肺癌小分子靶向药物的耐药机制和应对策略.来自全国各地从事肺癌和相关学科研究的600多位专家和学术带头人参加了此次会议.     

2010中国肺癌高峰论坛访谈录

为了进一步推动中国肺癌研究的发展,中国抗癌协会肺癌专业委员会和中国抗癌协会临床肿瘤学协作专业委员会于2010年3月11—13日在广州举行了第七届中国肺癌高峰论坛。此次会议的主题是非小细胞肺癌（non—small cell lung cancer,NSCLC）生物标志物的疗效预测：现实还是愿景？来自全国各地从事肺癌和相关学科研究的300多位专家和学术带头人参加了此次会议。     

2012中国肺癌高峰论坛访谈录

为了进一步推动中国肺癌研究的发展,中国抗癌协会肺癌专业委员会和中国抗癌协会临床肿瘤学协作专业委员会于2012年3月1-3日在广州举行了第九届中国肺癌高峰论坛。此次会议的主题是:小细胞肺癌,化石还是陨石?来自全国各地从事肺癌和相关学科研究的500多位专家和学术带头人参加了此次会议。相对于非小细胞肺癌如火如荼的发展现状而言,小细胞肺癌(small cell lung cancer,SCLC)     

2008中国肺癌高峰论坛访谈录

为了进一步推动中国肺癌研究的发展，中国抗癌协会肺癌专业委员会于2008年3月7—8日在深圳举行了第五届中国肺癌高峰论坛即2008中国肺癌高峰论坛。此次会议的主题是ⅢA期N2非小细胞肺癌的诊断和治疗。来自全国各地从事肺癌和相关学科研究的50多位专家和学术带头人参加了此次会议。     

2006中国肺癌高峰论坛访谈

为了进一步推动中国肺癌临床研究的发展，中国抗癌协会肺癌专业委员会于2006年2月24日在广州举行了第三届中国肺癌高峰论坛即2006中国肺癌高峰论坛。此次会议的主题是支气管肺泡细胞癌（bronchioloalveolar cell carcinoma．BAC）的诊断治疗问题。来自全国各地从事肺癌研究的40多位专家和学术带头人参加了此次会议。     

2009中国肺癌高峰论坛访谈录

为了进一步推动中国肺癌研究的发展,中国抗癌协会肺癌专业委员会于2009年3月12—14日在广东东莞举行了第六届中国肺癌高峰论坛。此次会议的主题为肺部孤立性结节（solitary pulmonary nodule,SPN）的诊断和治疗。来自全国各地从事肺癌和相关学科研究的50多位专家和学术带头人参加了此次会议。     

2005中国肺癌高峰论坛访谈

为了进一步推动中国肺癌临床研究的发展．中国抗癌协会肺癌专业委员会于2005年3月10-11日在珠海举办了第二届中国肺癌高峰论坛——2005中国肺癌高峰论坛。来自全国各地从事肺癌研究的40多位专家和学术带头人参加了此次会议。此次会议的主题是不可切除的局部晚期非小细胞肺癌(non-small cell lung cancer，NSCLC)的放化疗问题。     

2007中国肺癌高峰论坛访谈

为了进一步推动中国肺癌临床研究的发展，中国抗癌协会肺癌专业委员会于2007年3月8—10日在广州举行了第四届中国肺癌高峰论坛即2007中国肺癌高峰论坛。此次会议的主题是非小细胞肺癌（non—small cell lung cancer，NSCLC）孤立性转移灶的诊断和治疗。来自全国各地从事肺癌和相关学科研究的40多位专家和学术带头人参加了此次会议。     

2004中国肺癌高峰论坛访谈

为了推动中国的肺癌临床研究．中国抗癌协会肺癌专业委员会于2004年3月12～14日在广州举行了一次别开生面的学术研讨会—2004中国肺癌高峰论坛，来自全国各地从事肺癌研究的40多位专家和学术带头人参加了此次会议。此次会议的主题是非小细胞肺癌(non—small cell lung cancer，NSCLC)完全切除术后的辅助治疗问题。     

Antiviral therapy for ＂difficult-to-treat＂ hepatitis C virus-infected patients

Objective To review the updated research on direct antiviral agents （DAAs）-including regimens for hepatitis C virus （HCV）,and focus on ＂difficult-to-treat＂ HCV-infected patients.Data sources The literature concerning DAAs and hepatitis C cited in this review was collected from PubMed and Google Scholar databases published in English up to July 2013.Study selection Data from published articles regarding HCV and DAAs in clinical trials and in clinical use were identified and reviewed.Results It was recognized that some ＂difficult-to-treat＂ patients would still exist,even though stronger treatments using such as DAAs,including telaprevir and boceprevir,which lead to higher sustained virological response rates,are available.Such patients include those with advanced fibrosis/cirrhosis,elderly persons,children,HCV-human immunodeficiency virus co-infected patients,HCV-infected recipients,and so on.Conclusions Certain ＂difficult-to-treat＂ patients would still exist,even though stronger treatment is available.Although evidence from clinical trials is still lacking,interferon-sparing regimens could have stronger effects for eradicating HCV in such cases.     

Saffron （Crocus sativus L.） and major depressive disorder： a meta-analysis of randomized clinical trials

Due to safety concerns and side effects of many antidepressant medications, herbal psychopharmacology research has increased, and herbal remedies are becoming increasingly popular as alternatives to prescribed medications for the treatment of major depressive disorder （MDD）. Of these, accumulating trials reveal positive effects of the spice saffron （Crocus sativus L.） for the treatment of depression. A comprehensive and statistical review of the clinical trials examining the effects of saffron for treatment of MDD is warranted. OBJECTIVE： The purpose of this study was to conduct a meta-analysis of published randomized controlled trials examining the effects of saffron supplementation on symptoms of depression among participants with MDD. SEARCH STRATEGY： We conducted electronic and non-electronic searches to identify all relevant randomized, double-blind controlled trials. Reference lists of all retrieved articles were searched for relevant studies. INCLUSION CRITERIA： The criteria for study selection included the following： （1） adults （aged 18 and older） with symptoms of depression, （2） randomized controlled trial, （3） effects of saffron supplementation on depressive symptoms examined, and （4） study had either a placebo control or antidepressant comparison group. DATA EXTRACTION AND ANALYSIS： Using random effects modeling procedures, we calculated weighted mean effect sizes separately for the saffron supplementation vs placebo control groups, and for the saffron supplementation vs antidepressant groups. The methodological quality of all studies was assessed using the Jadad score. The computer software Comprehensive Meta- analysis 2 was used to analyze the data. RESULTS： Based on our pre-specified criteria, five randomized controlled trials （n = 2 placebo controlled trials, n = 3 antidepressant controlled trials） were included in our review. A large effect size was found for saffron supplementation vs placebo control in treating depressive symptoms （M ES = 1.62, P 〈 0.001）, revealing that saffron supplementation significantly reduced depression symptoms compared to the placebo control. A null effect size was evidenced between saffron supplementation and the antidepressant groups （M ES = -0.15） indicating that both treatments were similarly effective in reducing depression symptoms. The mean Jadad score was 5 indicating high quality of trials. CONCLUSION： Findings from clinical trials conducted to date indicate that saffron supplementation can improve symptoms of depression in adults with MDD. Larger clinical trials, conducted by research teams outside of Iran, with long-term follow-ups are needed before firm conclusions can be made regarding saffron＇s efficacy and safety for treating depressive symptoms.     

WHO西太区与世界中医药学会联合会中医名词术语国际标准比较研究：八纲辨证（三）

The Chinese characters 寒 and 热, 虚, and 实 are quite common concepts in Chinese language. However in traditional Chinese medicine （TCM）, they are used as four principles in syndrome differentiation. In terms of translation, 寒 and 热 are very easy to understand and can be simply translated as ＂cold＂ and ＂heat＂. But the transla- tion of 虚 and 实 used to be a problem. For a quite long time in translation practice,     

Relevance of muscle biopsy for diagnosing multifocal motor neuropathy

Multifocal motor neuropathy （MMN） is a rare,.focal,inflammatory,demyelinating disease of the peripheral nerves with pure motor involvementJ MMN is clinically characterized by slowly progressive,asymmetric,distal,upper limb predominant weakness,in the absence of sensory disturbances） Weakness is usually multifocal and connected to a distinct motor nerve,such as the musculocutaneous nerve resulting in biceps weakness,the posterior interosseus nerve resulting in finger drop,the median,ulnar,or radial nerve resulting in dexterity problems or grip weakness,or the peroneal nerve resulting in a foot drop.Onset of clinical manifestations is between 20 and 50 years of age.The prevalence of MMN is reported as 1-2 per 100 000.2 MMN is three times more frequent in men as compared to women.     

Large and giant medial sphenoid wing meningiomas involving vascular structures: clinical features and management experience in 53 patients

Background Large and giant medial sphenoid wing meningiomas that are located deeply in the skull base where they are closely bounded by cavernous sinus,optic nerve,and internal carotid artery make the gross resection hard to achieve.Also,this kind of meningiomas is often accompanied by a series of severe complications.Therefore,it was regarded as a formidable challenge to even the most experienced neurosurgeons.This study aimed to investigate the clinical features and management experience of patients with large and giant medial sphenoid wing meningiomas.Methods In this study,53 patients （33 female and 20 male,mean age of 47.5 years） with large and giant medial sphenoid wing meningiomas were treated surgically between April 2004 to March 2012,with their clinical features analyzed,management experience collected,and treatment results investigated retrospectively.Results In this study,gross total resection （Simpson Ⅰ and Ⅱ） was applied in 44 patients （83％）.Fifty-three patients had accepted the routine computed tomography scan and magnetic resonance imaging scan as postoperative neuroradiological evaluation.Their performance showed surgical complications of vascular lesions and helped us evaluate patients＇ conditions,respectively.Meanwhile,the drugs resisting cerebral angiospasm,such as Nimodipine,were infused in every postoperative patient through vein as routine.As a result,11 patients （21％） were found to have secondary injury of cranial nerves Ⅱ,Ⅲ,and Ⅳ,and nine patients got recovered during the long-term observing follow-up period.Temporary surgical complications of vascular lesions occurred after surgery,such as cerebral angiospasm,ischemia,and edema;24 patients （45％） appeared to have infarction and dyskinesia of limbs.Overall,visual ability was improved in 41 patients （77％）.No patient died during the process.Conclusions Microsurgical treatment may be the most effective method for the large and giant medial sphenoid wing meningiomas.The surgical strategy should focus on survival and postoperative living quality.     

Association between intervertebral disc degeneration and disturbances of blood supply to the vertebrae

Low back pain is a common public health problem in western industrialized societies and the world as well.Studies indicate that the prevalence rate ranges to 35%, with around 10% of patients from 12% becoming chronically disabled. It also places an enormous economic burden on society. Although the exact cause of low back pain has yet to be defined, intervertebral disc degeneration is considered a major source of it. Since patients with degenerative discs are often asymptomatic, the mechanisms of it are still unclear.     

基于SUV的PET对 4周期化疗后的弥漫大B细胞淋巴瘤患者预后的评估

在过去的十来年中,18氟脱氧葡萄糖（fluorodeoxyglucose,FDG）PET已经成为多种淋巴瘤疗效评价的有力工具,它主要通过视觉分析来评估疗效。修订后的判读标准适合评估化疗结束后的疗效。而不适用于化疗期间的疗效评价。     

痘苗病毒天坛株的减毒与其作为疫苗载体研究进展

1痘苗病毒天坛株的历史天花是人类历史上最可怕的传染病之一。天花由天花病毒（variola virus）引起,人是该病毒的惟一宿主。人感染天花病毒后的死亡率达到30%~40%[1]。世界上公认的对天花最早的准确记录来自中国,晋代药学家葛洪于公元430年左右,在《肘后备急方》中对天花有清楚的描述[1]。